159 related articles for article (PubMed ID: 35662114)
21. Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
Kimble EL; Cassaday RD
Leuk Lymphoma; 2021 Dec; 62(14):3333-3347. PubMed ID: 34402732
[TBL] [Abstract][Full Text] [Related]
22. Antibody therapy for acute lymphoblastic leukemia.
Portell CA; Advani AS
Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
24. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
25. Novel antibody therapy in acute lymphoblastic leukemia.
Kochuparambil ST; Litzow MR
Curr Hematol Malig Rep; 2014 Jun; 9(2):165-73. PubMed ID: 24623281
[TBL] [Abstract][Full Text] [Related]
26. Novel targets for treatment of adult acute lymphocytic leukemia.
Kasner MT
Curr Hematol Malig Rep; 2010 Oct; 5(4):207-12. PubMed ID: 20680526
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
28. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
29. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
30. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
Rafei H; Kantarjian HM; Jabbour EJ
Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic approaches for relapsed/refractory adult acute lymphoblastic leukemia (ALL), a review on monoclonal antibodies and targeted therapies.
Hosseini MS; Jafari L; Yami A; Gharehbaghian A
Indian J Cancer; 2022; 59(1):4-11. PubMed ID: 35645049
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
[TBL] [Abstract][Full Text] [Related]
35. Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies.
Tragiannidis A; Groll AH
Paediatr Drugs; 2021 Sep; 23(5):445-455. PubMed ID: 34292515
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
38. Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.
McClane J; Chawla A; Welch JJG
Pediatr Blood Cancer; 2022 Jun; 69(6):e29664. PubMed ID: 35293685
[TBL] [Abstract][Full Text] [Related]
39. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
40. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.
Curran E; Muffly L; Luskin MR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-11. PubMed ID: 35503981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]